Similarly, therapeutic blocking of CCL2/CCR2 axis against hepatocellular carcinoma inhibited the recruitment of inflammatory monocytes and tumor-associated macrophages, resulting in the reversal of the immunosuppressive TME and inactivation of antitumoral CD8+ T cell responses [210]. This evidence concerns the gene CCR2 and neoplasm.